Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1919 2
1939 3
1940 1
1945 1
1946 3
1947 1
1953 1
1956 1
1957 1
1958 2
1962 3
1963 1
1964 10
1965 3
1966 1
1967 1
1968 5
1969 8
1970 7
1971 8
1972 9
1973 14
1974 10
1975 4
1976 5
1977 3
1978 7
1979 11
1980 10
1981 5
1982 11
1983 9
1984 10
1985 13
1986 16
1987 17
1988 26
1989 16
1990 13
1991 10
1992 18
1993 31
1994 26
1995 16
1996 23
1997 16
1998 22
1999 22
2000 18
2001 31
2002 23
2003 25
2004 24
2005 37
2006 43
2007 54
2008 43
2009 41
2010 38
2011 46
2012 61
2013 65
2014 72
2015 57
2016 56
2017 64
2018 76
2019 91
2020 121
2021 110
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

1,530 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: mcdonald a. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Among authors: mcdonald a. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA; CGC, Hammond LJ, Zuccarino-Catania G. Motzer RJ, et al. Among authors: mcdonald a. J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. doi: 10.6004/jnccn.2019.0054. J Natl Compr Canc Netw. 2019. PMID: 31693980
Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback for urinary incontinence in women: multicentre randomised controlled trial.
Hagen S, Elders A, Stratton S, Sergenson N, Bugge C, Dean S, Hay-Smith J, Kilonzo M, Dimitrova M, Abdel-Fattah M, Agur W, Booth J, Glazener C, Guerrero K, McDonald A, Norrie J, Williams LR, McClurg D. Hagen S, et al. Among authors: mcdonald a. BMJ. 2020 Oct 14;371:m3719. doi: 10.1136/bmj.m3719. BMJ. 2020. PMID: 33055247 Free PMC article. Clinical Trial.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Among authors: mcdonald a. Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25. Lancet. 2017. PMID: 28129987 Free article. Clinical Trial.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: mcdonald aa. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT.
Hagen S, Bugge C, Dean SG, Elders A, Hay-Smith J, Kilonzo M, McClurg D, Abdel-Fattah M, Agur W, Andreis F, Booth J, Dimitrova M, Gillespie N, Glazener C, Grant A, Guerrero KL, Henderson L, Kovandzic M, McDonald A, Norrie J, Sergenson N, Stratton S, Taylor A, Williams LR. Hagen S, et al. Among authors: mcdonald a. Health Technol Assess. 2020 Dec;24(70):1-144. doi: 10.3310/hta24700. Health Technol Assess. 2020. PMID: 33289476 Free PMC article. Clinical Trial.
6-Hydroxydopamine: a far from simple neurotoxin.
Varešlija D, Tipton KF, Davey GP, McDonald AG. Varešlija D, et al. Among authors: mcdonald ag. J Neural Transm (Vienna). 2020 Feb;127(2):213-230. doi: 10.1007/s00702-019-02133-6. Epub 2020 Jan 1. J Neural Transm (Vienna). 2020. PMID: 31894418 Review.
1,530 results